# Questions, Answered From the Record > FAQ — Metabolic and Weight Research Peptides — Direct answers on semaglutide, retatrutide and AOD-9604: what each one is, how each acts on appetite and metabolism, approval status, and whether the evidence supports the claims. Metabolic and Weight Research Peptides, cited throughout. **COMMON QUESTIONS** Short answers to the questions readers arrive with, each traceable to the cited literature and none of them containing dosing guidance. ## What is semaglutide? Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist — a synthetic 31-amino-acid analogue of a hormone the intestine releases after a meal. Two backbone substitutions protect it from dipeptidyl peptidase-4, the enzyme that clears the native hormone within minutes, and a C18 fatty di-acid side chain binds it reversibly to serum albumin, which slows renal clearance and makes once-weekly administration workable. It is an approved prescription medicine in several indications and has the largest clinical trial record of the three compounds briefed on this site. ## What is semaglutide used for? It is approved by the FDA for type 2 diabetes mellitus, for chronic weight management, for reducing major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity, and, from 2025, for metabolic dysfunction-associated steatohepatitis. Each of those indications rests on a randomised trial: weight management on STEP 1 [4], cardiovascular risk reduction on SELECT [3] and, in diabetes, SUSTAIN-6 [7]. A separate trial in type 2 diabetes with chronic kidney disease also found reduced major kidney-disease events [2]. It is administered as a once-weekly subcutaneous injection or a once-daily oral tablet. ## How does semaglutide work? It occupies GLP-1 receptors in several tissues at once. At pancreatic beta cells it potentiates insulin secretion in a glucose-dependent manner, so the effect scales with blood sugar rather than firing regardless of it; at alpha cells it suppresses inappropriate glucagon release. On gastric smooth muscle and vagal afferents it slows gastric emptying, prolonging the sensation of fullness after a meal. And it reaches appetite-regulating regions of the brain directly. The glycaemic actions and the appetite actions are distinct mechanisms of the same molecule, which is why one compound carries both a diabetes and a weight indication. ## How does semaglutide work for weight loss? Primarily through the brain rather than the gut. Rodent mapping found semaglutide accessing the brainstem, area postrema, hypothalamic arcuate nucleus and parabrachial nucleus, where it activates appetite-suppressing POMC/CART neurons and inhibits appetite-driving NPY/AgRP neurons. The result was reduced food intake and altered food preference — with no fall in energy expenditure [6]. In other words the weight change comes from intake, not from burning more. In STEP 1, that mechanism produced a mean body-weight change of -14.9% at 68 weeks against -2.4% with placebo [4]. Because the effect depends on the signal being sustained, discontinuation is followed by substantial regain. ## Is Ozempic the same as semaglutide? Ozempic, Wegovy and Rybelsus are brand names for products whose active ingredient is semaglutide, so they are not different molecules and everything on this site about semaglutide's mechanism applies to each of them. They differ in formulation and in approved indication rather than in what the peptide does — the compound is marketed both as a once-weekly subcutaneous injection and as a once-daily oral tablet. Clinical trials are published under the compound name, which is why the STEP, SELECT, FLOW and SUSTAIN-6 results are reported here as semaglutide results [4][3][2][7]. ## What does retatrutide do? Retatrutide activates three receptors with one molecule: GIP, GLP-1 and glucagon. The GLP-1 and GIP arms suppress appetite and improve glucose-dependent insulin secretion, while controlled glucagon receptor activation adds energy expenditure and lipid mobilisation. In a 48-week Phase 2 obesity trial in 338 adults, the 12 mg arm produced a mean body-weight change of -24.2% against -2.1% with placebo [11]. In type 2 diabetes it lowered HbA1c by 2.02 percentage points at 24 weeks and body weight by 16.94% at 36 weeks [12], and in a liver-disease substudy it reduced liver fat by 82.4% at 24 weeks [10]. ## How does retatrutide work? Two of its three arms are conventional satiety mechanisms — the same slowed gastric emptying and central appetite suppression that define the incretin class. The third is not: glucagon receptor agonism raises energy expenditure and mobilises stored lipid, changing the output side of the equation rather than the input side. Structural work resolved the molecule bound to all three receptors and found it approximately 8.9 times more potent than native GIP at the GIP receptor but only 0.3 and 0.4 times as potent as the endogenous hormones at the glucagon and GLP-1 receptors [9]. Balance across three receptors, not maximal potency at one, is what the design optimises. ## How to reconstitute retatrutide? This site does not publish reconstitution, handling or administration procedures for any compound, and this answer is not an exception. Retatrutide is investigational: it has no approved formulation, no approved dosing and no approved preparation standard, and every published efficacy figure comes from material manufactured, characterised and administered under clinical-trial conditions — in Phase 2 as a once-weekly subcutaneous injection [11]. Material obtained outside a trial has no verified identity, concentration, purity or sterility, so a preparation procedure would not make the resulting solution equivalent to what was studied. Readers looking for procedural guidance should consult a qualified clinician or the relevant trial protocol rather than a research digest. ## Is retatrutide FDA approved? No. Retatrutide is investigational and has not been approved by the FDA or any other regulator. It has completed Phase 2 trials in obesity [11], type 2 diabetes [12] and metabolic liver disease [10], and is in Phase 3 through the TRIUMPH programme, with dedicated cardiovascular and kidney outcome trials ongoing [8]. This matters for how the figures on this site should be read: everything reported for retatrutide comes from clinical trials rather than approved labelling, and long-term safety, cardiovascular outcomes and durability of weight loss after discontinuation are unresolved rather than merely unpublished. ## What is AOD-9604? AOD-9604 is a synthetic 16-amino-acid peptide modelled on the C-terminal lipolytic domain of human growth hormone — residues 177-191, with an N-terminal tyrosine substituted for the native phenylalanine and an intramolecular disulfide bridge reproducing the parent hormone's cystine loop. It was developed as an oral anti-obesity drug candidate and does not bind the growth hormone receptor, which is the design feature intended to avoid the growth-promoting and diabetogenic effects of the intact hormone. It is not approved for any indication anywhere, is sold as research material, and is prohibited at all times in sport as a growth-hormone fragment. ## What does the peptide AOD9604 do? In rodent models it acts on fat tissue: inhibiting the synthesis of new fat via acetyl-CoA carboxylase, increasing fat oxidation, and up-regulating beta-3 adrenergic receptor expression in white adipose tissue. Chronic treatment reduced body weight and fat in obese mice, and that chronic effect disappeared in beta-3 adrenergic receptor knockout animals while acute increases in energy expenditure and fat oxidation persisted [16]; a companion study reported increased fat oxidation and weight loss in obese mice [17]. In humans it has demonstrated tolerability comparable to placebo [15] but not weight loss. It has no documented action on appetite circuits. ## Does AOD-9604 actually work? Not for weight loss in humans, on the published evidence. The pivotal Phase IIb obesity trial did not show statistically significant weight loss against placebo, and the development programme was discontinued. What the human data do establish is safety: across roughly six trials totalling about 900 adults with obesity, at daily amounts from 0.25 mg to 54 mg for 7 days to 24 weeks, tolerability was indistinguishable from placebo and none of the adverse effects associated with full-length growth hormone appeared [15]. A large safety dataset attached to a failed efficacy endpoint is not evidence of benefit, and community reports point the same way — the most common one is that no meaningful fat loss occurs. ## How does AOD-9604 work? By a mechanism that never touches the satiety pathway. The foundational literature characterises the growth-hormone C-terminal fragment as primarily antilipogenic — inhibiting fat synthesis — rather than directly lipolytic, with the chronic weight effect in mice dependent on functional beta-3 adrenergic signalling [16] and an accompanying increase in fat oxidation [17]. Non-clinical work found an intravenous half-life of about 3 minutes, degradation by sequential removal of N-terminal amino acids, and no genotoxic or toxicological concerns in rats and primates [14]. There is no arcuate nucleus, no brainstem access and no delayed gastric emptying in that account, which is the clearest single difference between this compound and the two incretin agonists. --- An independent briefing desk on the satiety literature: pitaspeptides reports what the trials measured, what research communities report, and where the record stops — it is not a clinic, not a pharmacy, and not medical advice.